February 11, 2025 09:25 AM ESTUpdated 12:05 PM

Inventiva cuts pipeline, lays off nearly entire research team in bid to get to Phase 3 MASH readout

Max Gelman

Senior Editor

Inventiva is trimming its pipeline and enacting layoffs in an effort to get its lead MASH drug approved, the company

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

FDA approves Moderna’s next-gen Covid vaccine, with limits on most healthy people

Summit says bispecific misses overall survival in closely-watched lung cancer study

Summit’s disappointing survival readout raises stakes for full data

Gilead, Merck reveal 'practice-changing' data for Trodelvy-Keytruda combo in aggressive breast cancer

Arvinas, Pfizer's PROTAC in breast cancer no better than oral SERDs

sponsored

From weeks to days: how Aizon Intelligent Agents transform pharma validation